Stem-Cell-Based Therapies for Nerve Regeneration

A special issue of Cells (ISSN 2073-4409). This special issue belongs to the section "Cells of the Nervous System".

Deadline for manuscript submissions: closed (15 February 2023) | Viewed by 2439

Special Issue Editor


E-Mail Website
Guest Editor
1. Department of Molecular Pharmacology, Albert Einstein College of Medicine, Bronx, NY, USA
2. School of Pharmaceutical Sciences, Wenzhou Medical University, Wenzhou, China
Interests: molecular pharmacology; biomaterials; growth factor; autophagy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Traumatic events, iatrogenic injuries, and neurodegenerative diseases can lead to axonal degeneration, inflammation, neuron death, and cytoarchitectural malformation in both the peripheral nervous system (PNS) and central nervous system (CNS). Conventional medical therapies have limited efficacy in supporting functional recovery from nervous damage because the mature nervous system lacks the necessary precursor cells to generate new neurons and glial cells. Recently, stem-cell-based strategies have heralded potential new therapeutic approaches for addressing nerve regeneration and repair.

In this Special Issue, we are interested in original works, protocols, literature reviews, and meta-analyses related to stem-cell therapies for brain injury, spinal cord injury, peripheral nerve injury and neurodegenerative diseases.

The topics of interest for this Special Issue include, but are not limited to:

  1. Mesenchymal stem cells (MSCs) such as dental pulp stem cells (DPSCs) used for the stem-cell therapies in nerve diseases.
  2. Stem-cell-based strategies in combination with novel technologies (e.g., precisely controlled hydrogels and growth factors) focused on the treatment of nerve diseases.
  3. The application of stem-cell-derived products (e.g., apoptotic bodies and exosomes) in nerve diseases.
  4. Biomaterials derived from stem cells focused on repair and regeneration in nerve injury.

Dr. Zhouguang Wang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cells is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

16 pages, 3482 KiB  
Article
Stem Cell Factor and Granulocyte Colony-Stimulating Factor Promote Remyelination in the Chronic Phase of Severe Traumatic Brain Injury
by Xuecheng Qiu, Suning Ping, Michele Kyle, Lawrence Chin and Li-Ru Zhao
Cells 2023, 12(5), 705; https://doi.org/10.3390/cells12050705 - 23 Feb 2023
Cited by 3 | Viewed by 2163
Abstract
Severe traumatic brain injury (TBI) causes long-term disability and death in young adults. White matter is vulnerable to TBI damage. Demyelination is a major pathological change of white matter injury after TBI. Demyelination, which is characterized by myelin sheath disruption and oligodendrocyte cell [...] Read more.
Severe traumatic brain injury (TBI) causes long-term disability and death in young adults. White matter is vulnerable to TBI damage. Demyelination is a major pathological change of white matter injury after TBI. Demyelination, which is characterized by myelin sheath disruption and oligodendrocyte cell death, leads to long-term neurological function deficits. Stem cell factor (SCF) and granulocyte colony-stimulating factor (G-CSF) treatments have shown neuroprotective and neurorestorative effects in the subacute and chronic phases of experimental TBI. Our previous study has revealed that combined SCF and G-CSF treatment (SCF + G-CSF) enhances myelin repair in the chronic phase of TBI. However, the long-term effect and mechanism of SCF + G-CSF-enhanced myelin repair remain unclear. In this study, we uncovered persistent and progressive myelin loss in the chronic phase of severe TBI. SCF + G-CSF treatment in the chronic phase of severe TBI enhanced remyelination in the ipsilateral external capsule and striatum. The SCF + G-CSF-enhanced myelin repair is positively correlated with the proliferation of oligodendrocyte progenitor cells in the subventricular zone. These findings reveal the therapeutic potential of SCF + G-CSF in myelin repair in the chronic phase of severe TBI and shed light on the mechanism underlying SCF + G-CSF-enhanced remyelination in chronic TBI. Full article
(This article belongs to the Special Issue Stem-Cell-Based Therapies for Nerve Regeneration)
Show Figures

Figure 1

Back to TopTop